BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections.
Hameed P S, Kotakonda H, Sharma S, Nandishaiah R, Katagihallimath N, Rao R, Sadler C, Slater I, Morton M, Chandrasekaran A, Griffen E, Pillai D, Reddy S, Bharatham N, Venkatesan S, Jonnalagadda V, Jayaraman R, Nanjundappa M, Sharma M, Raveendran S, Rajagopal S, Tumma H, Watters A, Becker H, Lindley J, Flamm R, Huband M, Sahm D, Hackel M, Mathur T, Kolamunnage-Dona R, Unsworth J, Mcentee L, Farrington N, Manickam D, Chandrashekara N, Jayachandiran S, Reddy H, Shanker S, Richard V, Thomas T, Nagaraj S, Datta S, Sambandamurthy V, Ramachandran V, Clay R, Tomayko J, Das S, V B.
Hameed P S, et al. Among authors: v b.
Nat Commun. 2024 Sep 18;15(1):8202. doi: 10.1038/s41467-024-52557-2.
Nat Commun. 2024.
PMID: 39294149
Free PMC article.
Clinical Trial.
The global crisis of antimicrobial resistance (AMR) necessitates the development of broad-spectrum antibacterial drugs effective against multi-drug resistant (MDR) pathogens. ...BWC0977 exhibited a minimum inhibitory concentration (MIC(90)) of 0.03-2 g/mL against a glob …
The global crisis of antimicrobial resistance (AMR) necessitates the development of broad-spectrum antibacterial drugs effective agai …